Evidence mapPaperPMID 41384289Full record

ReviewMolecular medicine reports2026

Influence and treatment of insulin receptor substrate/PI3K/Akt‑mediated insulin resistance in diabetes mellitus (Review).

Weikang Tang, Huixia Liu, Xuan Li, Siyao Deng, Changyu Gao

Abstract readReview
In one paragraph

Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weikang TangSchool of Medicine, Tarim University, Alaer, Xinjiang Uyghur Autonomous Region 843300, P.R. China.
Huixia LiuSchool of Medicine, Tarim University, Alaer, Xinjiang Uyghur Autonomous Region 843300, P.R. China.
Xuan LiSchool of Medicine, Tarim University, Alaer, Xinjiang Uyghur Autonomous Region 843300, P.R. China.
Siyao DengSchool of Medicine, Tarim University, Alaer, Xinjiang Uyghur Autonomous Region 843300, P.R. China.
Changyu GaoDepartment of Prescription Science, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a metabolic disorder that has notable impacts on human health. Since improving insulin sensitivity and metabolic homeostasis is important for the treatment of diabetes and its complications, there is a need to evaluate therapies that improve insulin resistance. The aim of the present review was to introduce the effects of the insulin receptor substrate (IRS)/PI3K/Akt pathway on insulin resistance by summarizing and evaluating all existing insulin signaling pathway studies as the entry point, and to integrate the processes and mechanisms through which drugs alleviate insulin resistance. Peer‑reviewed studies and reports on diabetes, insulin resistance and drug therapy were retrieved by searching websites such as PubMed (https://pubmed.ncbi.nlm.nih.gov/) and China National Knowledge Infrastructure (CNKI, https://www.cnki.net/), as well as by a manual search. The present review discusses the association between diabetes and the IRS/PI3K/Akt pathway, the treatment of diabetes by regulating this pathway to alleviate insulin resistance, the process and mechanism of combining drugs to alleviate insulin resistance, including natural compounds, Traditional Chinese Medicine and active ingredients, and the latest modern treatment methods. In conclusion, the present review summarizes the potential role of the IRS/PI3K/Akt pathway in the treatment of diabetes through its effect on insulin resistance and elucidates the therapeutic effects of drugs targeting this pathway.

Indexed as

Diabetes MellitusInsulin Receptor Substrate ProteinsInsulin ResistancePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAnimalsHumansHypoglycemic AgentsInsulinSignal TransductionHypoglycemic AgentsInsulinInsulin Receptor Substrate ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktdiabetes mellitusinsulin receptor substrate/PI3K/Aktinsulin resistancesignal transduction

Identifiers

PMID41384289
PMCPMC12744929

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.